Drawing for GENSTO

USPTO serial 85220130

GENSTO

Reviewed by CopyMark Law Group

Reg. 4085067Status 710
Filing date
Status date
Registration date
Jan 10, 2012
Examiner
BUSH, KAREN K
Law office
TMEG LAW OFFICE 108

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with GENSTO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Steven M. Rabin

STEVEN M. RABIN RABIN & BERDO, P.C.1101 14TH ST NW STE 500WASHINGTON, DC 20005-5633UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Adjuvants for medical purposes; Antiallergic medicines; Anti-cancer preparations; Medicinal herbal extracts for medical purposes; Pharmaceutical and medicinal preparations and substances for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Pharmaceutical and medicinal preparations for the treatment of brain diseases or disorders and autoimmune diseases or disorders; Dietary and nutritional supplements for medical use; Dietary supplements for treating fatigue or liver support; Animal feed additive for use as a nutritional supplement for medical purposes; Dietary supplements for human consumption or for animals; Nutritional additives for medical purposes for use in foods for human consumption or for animals; Animal feed supplements; Dietary pet supplements in the form of pet treats; Fungi preparations for medical or veterinary use for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Pharmaceutical preparations and substances for veterinary purposes for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Chemical preparations for medicinal purposes for treating disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, ocular disorders, brain diseases or disorders, autoimmune diseases or disorders, or bone diseases, for use in dermatology, oncology, hematology and ophthalmology and for gastroenterological disorders or liver ailments; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Pharmaceuticals preparations for the treatment of kidney diseasesSECTION 8 - CANCELLEDJul 26, 2011

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 22, 2022CAEXCANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9—
Jan 10, 2021REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Jul 3, 2017NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Jul 3, 2017C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jul 3, 2017APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 8, 2017E815TEAS SECTION 8 & 15 RECEIVED—
Jan 10, 2017REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 10, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 7, 2011SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 6, 2011REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
Nov 28, 2011CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Nov 19, 2011SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Nov 16, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 10, 2011IUAFUSE AMENDMENT FILED—
Nov 10, 2011EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 20, 2011NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 26, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 26, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 17, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 16, 2011ALIEASSIGNED TO LIE—
Jun 2, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 24, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 24, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 24, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 7, 2011GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 7, 2011GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 7, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 6, 2011DOCKASSIGNED TO EXAMINER—
Jan 24, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 21, 2011NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance